Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary data
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gratwohl, A.
Right arrow Articles by Urbano-Ispizua, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gratwohl, A.
Right arrow Articles by Urbano-Ispizua, A.
Related Collections
Right arrow 2004 - Editors Choice
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:653-660, 2004
© 2004 European Society for Medical Oncology

Original Paper

Hematopoetic stem cell transplantation for solid tumors in Europe

Received 11 November 2003; accepted 23 December 2003

Background:

Hematopoetic stem cell transplants (HSCT) are discussed as treatment options for patients with solid tumors. Transplant numbers have changed substantially over the last decade, few controlled studies are available and different opinions prevail. Objective information on current practice is needed.

Patients and methods:

Data from 27 902 HSCT for solid tumors (2% allogeneic, 98% autologous), collected by the European Group for Blood and Marrow Transplantation (EBMT) activity survey from 1991 to 2002 were used to assess trends, transplant rates and coefficient of variation of transplant rates in Europe.

Results:

Transplant numbers increased from 536 in 1991 to 4154 in 1997 and decreased to 1913 in 2002. Indications were neuroblastoma (2504 HSCT; 9%), glioma (662 HSCT; 2%), soft tissue sarcoma (1253 HSCT; 4%), germ cell cancer (3291 HSCT; 12%), breast cancer (13 524 HSCT; 48%), Ewing’s sarcoma (1896 HSCT; 7%), lung cancer (387 HSCT; 1%), ovarian cancer (845 HSCT; 3%) and other solid tumors (3540 HSCT; 14%). Allogeneic cells were used in <20 cases up to 1997; since then allogeneic HSCT increased to 159 in 2002, mainly for renal cell carcinoma. Low coefficients of variation in transplant rates (<60%) are observed for Ewing’s sarcoma (<56.5%), suggesting consensus for this indication.

Conclusions:

These data give an overview on current practice of HSCT for solid tumors in Europe. They provide objective information for health-care providers and patient counselling.

A. Gratwohl1,*, H. Baldomero1, T. Demirer2, G. Rosti3, G. Dini4, R. Ladenstein5 and A. Urbano-Ispizua6

1 Division of Hematology, Department of Internal Medicine, Kantonsspital Basel, Switzerland; 2 EBMT Office, Ankara University Medical School, Ibn-i Sina Hospital, Sihhiye, Ankara, Turkey; 3 Oncology–Hematology Department, Ospedale Civile, Ravenna; 4 Department of Pediatric Hematology & Oncology, Institute G. Gaslini, Genova, Italy; 5 BMT Unit, St Anna Kinderspital, Vienna, Austria; 6 EBMT Secretariat, Hospital Clinic, Barcelona, Spain

Key words: donor type, Europe, hematopoetic stem cell transplants, solid tumors, transplant rates


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
H.-J. Kolb
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Blood, December 1, 2008; 112(12): 4371 - 4383.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
Z. Lee, J. E. Dennis, and S. L. Gerson
Imaging Stem Cell Implant for Cellular-Based Therapies
Experimental Biology and Medicine, August 1, 2008; 233(8): 930 - 940.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Pedrazzoli, J. Ledermann, J-P Lotz, S Leyvraz, M Aglietta, G Rosti, K. Champion, S Secondino, F Selle, N Ketterer, et al.
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
Ann. Onc., October 1, 2006; 17(10): 1479 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. McTiernan, D. Driver, M. P. Michelagnoli, A. M. Kilby, and J. S. Whelan
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours
Ann. Onc., August 1, 2006; 17(8): 1301 - 1305.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Barkholt, M. Bregni, M. Remberger, D. Blaise, J. Peccatori, G. Massenkeil, P. Pedrazzoli, A. Zambelli, J.-O. Bay, S. Francois, et al.
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
Ann. Onc., July 1, 2006; 17(7): 1134 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Kami, A. Makimoto, Y. Heike, and Y. Takaue
Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies
Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. W. Childs
Evolving trends in hematopoietic cell transplantation for solid tumors: tempering enthusiasm with clinical reality
Ann. Onc., April 1, 2004; 15(4): 543 - 544.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.